Previous 10 | Next 10 |
Furthers mid- and long-term growth with strategic advance into pharmacogenomics and mental health Castle executive management to host conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovat...
TissueCypher is Castle’s fourth test to receive ADLT status Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Centers for Medicare & Medicaid Services (CMS) granted Advanc...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced upcoming presentations on two of its skin cancer gene expression profile (GEP) tests at the 2022 American Academy of Dermatology (AAD) Annual Meeting, be...
On Friday, the commercial-stage diagnostics company, Castle Biosciences (NASDAQ:CSTL), announced new data to claim that its gene expression profile test, DecisionDx-Melanoma, performed better than T-stage at identifying patients with low risk of sentinel lymph node positivity. The data suppor...
Study demonstrated that DecisionDx ® -Melanoma can better identify sentinel lymph node positivity risk, potentially allowing for more precise and personalized management of melanoma patients and improved patient selection for the SLNB surgical procedure Castle Biosc...
Castle Biosciences, Inc. (CSTL) Q4 2021 Earnings Conference Call February 28, 2022 4:30 P.M. ET Company Participants Camilla Zuckero - Executive Director of Investor Relations and Corporate Communications Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Fin...
Castle Biosciences press release (NASDAQ:CSTL): Q4 GAAP EPS of -$0.25 beats by $0.23. Revenue of $25M (+44.5% Y/Y) beats by $0.85M. For further details see: Castle Biosciences GAAP EPS of -$0.25 beats by $0.23, revenue of $25M beats by $0.85M
Full-year 2021 revenue was up 50% over 2020 to $94.1 million, beating expectations Growth of 55% year over year in total GEP testing volume Full-year 2022 revenue is expected to be between $115-120 million Conference call and webcast today at 4:30 p.m. ET Castle Biosci...
Castle Biosciences (NASDAQ:CSTL) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close. The consensus EPS Estimate is -$0.48 (-108.7% Y/Y) and the consensus Revenue Estimate is $24.15M (+39.6% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward r...
Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary – PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few years. Countries are racing to slow down the spread...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...